Time to all-cause discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

被引：0
|
作者：
Swartz, MS
Ascher-Svanum, H
Faries, DE
Tunis, SL
Landbloom, R
Swanson, J
机构：
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA
[2] Eli Lilly & Co, Outcomes Res, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co, Neurosci, Indianapolis, IN 46285 USA
来源：
BIOLOGICAL PSYCHIATRY | 2005年 / 57卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
153
引用
收藏
页码：44S / 44S
页数：1
相关论文
共 50 条
  • [21] Typical versus atypical antipsychotics
    Luchins, D
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (10): : 1927 - 1927
  • [22] TREATMENT PERSISTENCE AND DISCONTINUATION RISK OF TYPICAL DEPOT AND ATYPICAL LONG-ACTING ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA IN POLAND
    Wierzbicka, N.
    Jakubczak, P.
    Krupa, D.
    Burski, J.
    Skrzekowska-Baran, I
    Czech, M.
    VALUE IN HEALTH, 2016, 19 (07) : A526 - A526
  • [23] All-cause mortality associated with atyical and typical antipsychotics in demented outpatients
    Trifiro, Gianluca
    Verhamme, Katia M. C.
    Ziere, Gijsbertus
    Caputi, Achille P.
    Stricker, Bruno H. Ch
    Sturkenboom, Miriam C. J. M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (05) : 538 - 544
  • [24] Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia A Naturalistic, Comparative Study
    Chan, Hung-Yu
    Pan, Yi-Ju
    Chen, Jiahn-Jyh
    Chen, Chiung-Hsu
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (01) : 13 - 20
  • [25] Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia
    Fujimaki, Koichiro
    Takahashi, Terumichi
    Morinobu, Shigeru
    PLOS ONE, 2012, 7 (05):
  • [26] Treatment Persistence Associated with Typical versus Atypical Antipsychotics among Out-patients with Schizophrenia
    Adeosun, Increase Ibukun
    BRITISH JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 10 (04):
  • [27] All-Cause Treatment Discontinuation and Other Effectiveness Measures
    McEvoy, Joseph P.
    CNS SPECTRUMS, 2006, : 6 - 7
  • [28] Number needed to treat (NNT) for all-cause medication discontinuation from randomized controlled trials comparing olanzapine to other antipsychotics for the treatment of schizophrenia
    Stauffer, Virginia
    Karagianis, Jamie
    Sutton, Virginia
    Ascher-Svanum, Haya
    Treuer, Tamas
    Silva de Lima, Mauricio
    Poole-Hoffmann, Vicki
    Tohen, Mauricio
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 259S - 259S
  • [29] Time to all-cause discontinuation following randomization to open-label olanzapine, risperidone, or conventional antipsychotic treatment for schizophrenia
    Ascher-Svanum, H
    Nyhuis, AW
    Tunis, SL
    Stevens, M
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 44S - 44S
  • [30] Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
    Davis, Sonia M.
    Stroup, T. Scott
    Koch, Gary G.
    Davis, Clarence E.
    Rosenheck, Robert A.
    Lieberman, Jeffrey A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 253 - 265
12345